What This Study Examined

Researchers followed 27 individuals with LAMA2-RD and 11 individuals with SELENON-RM, ranging in age from 3 to 50 years, over four visits spaced six months apart. At each visit, the study team measured muscle strength (using both manual muscle testing and a hand-held strength-measuring device), a range of functional tests (including a standardized motor function scale, walking distance and speed, timed stair climbing, and rising from the floor), daily activity levels using wearable accelerometers, and quality of life, pain, and fatigue through questionnaires. The goal was to determine which of these measures could reliably detect meaningful change over time, since a clinical trial can only succeed if it uses measures sensitive enough to show a treatment is working.

Key Findings

Over the 1.5-year study period, most measures of muscle strength and function remained largely stable in individuals with LAMA2-RD, suggesting that measurable decline in this condition happens slowly.
In SELENON-RM, a small number of measures did show a modest but statistically meaningful decline over the study period: the overall motor function score, the portion of that score reflecting standing and transfers, and the distance participants could walk in six minutes.
Several other functional and balance tests included in the study were found to be poorly suited for tracking either condition — either because they were too difficult for more affected individuals to attempt, or because most participants' scores were already at the floor or ceiling of the scale from the start.
Muscle strength measured with the hand-held device actually increased slightly in several muscle groups in both groups during the study. The research team attributes this to normal growth and development in younger participants working alongside — and partially masking — the slow effects of the underlying disease, rather than to any improvement in the condition itself.
Wearable activity trackers picked up on subtle changes in daily activity levels among individuals with LAMA2-RD, even during periods when standard clinic-based tests showed no change, suggesting these devices may offer valuable, complementary information for future studies.

Why This Matters

Before any new treatment for LAMA2-RD or SELENON-RM can be properly tested in a clinical trial, researchers first need reliable ways to measure whether that treatment is working. This study is a foundational step in that direction: by carefully tracking a wide range of measurements over time, the research team identified which ones are sensitive enough to detect real change in each condition, and which ones are not.

The finding that both conditions progress quite slowly is, in one sense, reassuring for individuals and families managing day-to-day care. At the same time, it presents a real challenge for clinical trial design, since a typical trial lasts only one to two years — a period during which many of these outcome measures may not detect meaningful change even if a treatment is having a genuine effect. This underscores the importance of continuing to develop more sensitive tools, including muscle imaging and wearable activity monitors, and explains why the research team is already conducting a longer, five-year follow-up study. Work like this — patient, methodical, and unglamorous as it may be — is exactly the kind of groundwork that needs to happen before any future treatment can be fairly and successfully evaluated.

Help Fuel CMD Progress Now

Research like this moves forward because people choose to fund it.

Right now, Cure CMD is actively reviewing research projects to fund in 2026. Your donation today helps us invest in the most promising science, moving discoveries like this one closer to real treatments and therapies.

Donate today to help accelerate CMD research: curecmd.org/2026

Behind every study are researchers working with urgency, care, and a deep commitment to this community.

Want to meet some of the people behind the science? Watch our Spotlight series on CMD Researchers to hear directly from the scientists pushing this work forward: https://bit.ly/CMDResearcherSpotlight

LAMA2 & SELENON: New Research, August 2026